Research
Hormonal
Carbonic anhydrase inhibitors such as acetazolamide reduce OSA severity by 40-50% in patients with high loop gain.
If you have high loop gain OSA, ask your doctor about carbonic anhydrase inhibitors like acetazolamide. These can reduce your apnea severity by 40-50% by stabilizing your breathing control. Be aware of potential side effects like tingling or stomach upset.
ModerateSupportsMEDIUM confidence
Carbonic anhydrase inhibitors such as acetazolamide and sulthiame reduce loop gain and OSA severity by ~ 40–50% [159–162]
Why this rating
Based on multiple studies, but specific trial details are not fully elaborated in this review.
Source
Developments in Pharmacotherapy for Obstructive Sleep Apnoea: Unlocking the Potential for Targeted Treatment
Danny J. Eckert · Drugs · 2025
DOI 10.1007/s40265-025-02268-9
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →